RankAlpha logo
Back to Rankings

PVLA

Palvella TherapeuticsC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
PVLA now has positive Phase 3 SELVA data, an intended 2H 2026 NDA, and materially improved liquidity after the February 2026 financing, which together support a credible path to a first commercial product in a disease with no FDA-approved therapies [#PR-2026-02-24][#PR-2026-03-31].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +4.7.
What can break
Commercial launch execution risk if approved in a rare-disease market.
Momentum
51
Value
41
Sentiment
70
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $125.00 · Bull $185.00 · Bear $70.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $224.00
Why
Momentum51 · Δ7d -11.5
Value41 · Δ7d +0.1
Sentiment70 · Δ7d +4.7
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
51
34% active weight
Current posture
7d trendSoftening
Δ7d
-11.5
Δ21d
-36.7
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
70
33% active weight
Current posture
7d trendImproving
Δ7d
+4.7
Δ21d
+17.1
Why this grade

Composite grade C. Momentum 50.7 / Value 41.1 / Sentiment 70.0

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$1.61B
Beta
-0.15
Shares Out
11.84M
P/E (TTM) · Derived
-17.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-57.65
Rev YoY
-100.0%
EPS YoY
+74.0%
Gross Margin
-
Op Margin
-26594.3%
Net Debt
-$71.66M
Current Ratio
6.49
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology